| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 162.9 | 3.3 |
| Profit before tax | 124.7 | -34.7 |
| Net income | 124.6 | -34.7 |
| EPS (diluted, $ a share) | $1.11 | $-0.34 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +4895.9% |
|---|---|
| Operating margin | 76.0% |
10-Q filed with the SEC, NASDAQ: ALEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alector, Inc.: key numbers
- Share price
- $2.57Close, Nov 16
- Market cap
- $383M
- Shares outstanding
- 148.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alector, Inc.
All →Alector Financial Results
Alector reported Q3 2026 financial results, highlighting a cash position of $138.7 million and a runway extended into the second half of 2029 following a $100 million licensing deal with Genentech and a $75 million equity offering. The company is transitioning its pipeline to focus entirely on its Alector Brain Carrier (ABC) platform, with lead candidate AL137 expected to enter first-in-human dosing by April 2027.
- Term
- Q3 2026
“Since our last quarterly update, we exclusively licensed AL050 to Genentech, strengthened our balance sheet, and moved our wholly owned programs closer to the clinic. The Alector Brain Carrier is designed to address one of the central challenges in treating neurodegenerative disease: delivering enough drug to the brain.”
Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector
Alector Capital Raise of $75M
Alector, Inc. entered into an underwriting agreement to sell 36,600,000 shares of common stock in a public offering at $2.05 per share. The company expects to receive gross proceeds of approximately $75 million to fund research, development, and general corporate purposes. The offering includes participation from institutional investors including TCGX and BVF Partners.
- Value
- $75M
- Counterparty
- Morgan Stanley & Co. LLC
Alector Stock Plan Amendment
Alector, Inc. approved a stock option repricing for current employees, including the CEO and Chief Accounting Officer, for options with exercise prices above $1.87. The new exercise price is set at $1.87, the current market closing price, subject to a one-year retention period to motivate and retain staff. Approximately 4.05 million shares are affected by this repricing, which previously had exercise prices as high as $33.11.
- Term
- 1 year
Alector Licensing Deal with Genentech, Inc. Worth $100M
Alector entered into an exclusive global licensing agreement with Genentech to develop and commercialize AL050, a brain-penetrant engineered GCase enzyme replacement therapy for Parkinson’s disease. Alector will receive a $100 million upfront payment and is eligible for up to $1.17 billion in additional milestone payments plus tiered royalties on net sales. The deal extends Alector's cash runway into 2029 while allowing the company to retain ownership of its proprietary Alector Brain Carrier platform.
- Value
- $100M
- Counterparty
- Genentech, Inc.